If you have been reading about metabolic research and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-06-22. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; may appear as cake |
| Solubility class | Water-soluble | Often reconstituted in aqueous buffer |
| Typical storage temperature | −20 °C or below | Protect from light and moisture |
| Typical analytical method | RP-HPLC and mass spectrometry | Used for purity and identity |
| Common synonyms | AOD-9604; AOD9604; hGH fragment 176-191 | Research name and fragment description |
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
=== Gawker === In May 2016, Ayyadurai filed suit against Gawker Media for $35 million, alleging that their website Gawker published "false and defamatory statements", causing "substantial damage to Dr. Ayyadurai's personal and professional reputation and career". The filing also named writer Sam Biddle, executive editor John Cook, and Gawker founder and CEO Nick Denton. Gawker Media responded that, "These claims to have invented email have been repeatedly debunked by the Smithsonian Institute [sic], Gizmodo, the Washington Post and others." In November 2016, the by-then-bankrupt Gawker Media settled the lawsuit with Ayyadurai for $750,000 as part of a broader settlement with wrestler Hulk Hogan and journalist Ashley Terrill, all of whom were represented by attorney Charles Harder. In a statement, Ayyadurai said that "history will reflect that this settlement is a victory for truth". Biddle denounced the settlement and said he fully stood by his reporting. Denton wrote that "we expected to prevail" in the Ayyadurai and Terrill lawsuits, "but all-out legal war with" billionaire Peter Thiel, who financially backed Harder, was untenable in terms of cost, time and human toll. Katie Hafner, the author of several books on Internet history—including one on the development of ARPANET email—said, "This situation is both bizarre and appalling in that here we are simply trying to get the record straight, and [Ayyadurai has] managed to make money off claims that appear to be misleading."
== Treatment == The primary treatment for urethral diverticulum is surgical. In women, the surgery is conducted transvaginally, usually when there is no acute inflammation to better aid dissection of the delicate tissues.
In 2009, Valve hired IceFrog, the developer of Defense of the Ancients, a Warcraft III mod. IceFrog led the development of a sequel not associated with the Warcraft elements, Dota 2, released in 2013. Alongside Dota 2 in 2011, Valve started the International, an annual esports tournament for Dota 2 with a prize pool supported by Valve and funds from microtransactions from battle passes purchased by players. Valve released Portal 2 in April 2011. As with the original Portal, Valve employed a Digipen student team to help develop it; the team behind Tag: The Power of Paint implemented the new gel gameplay. In April 2010, Valve launched Steam for Mac OS X along with ports of several of its games including the Half-Life series. The Screen Digest analyst Ed Barton estimated Valve's 2010 revenue to be in the "high hundreds of millions of dollars". As of 2011, Valve had an estimated worth of $2 to 4 billion and employed 250 people; according to Newell, this made it more profitable per employee than Google or Apple. Most of Valve's revenue came from Steam, which controlled 50 to 70% of the market for downloaded PC games in 2011. By 2011, Valve had replaced episodic development with a platform-oriented approach, whereby games such as Left 4 Dead 2 and Team Fortress 2 were continually updated through Steam updates. In June 2012, Valve hired the economist Yanis Varoufakis to study the online economies of their games. That December, Valve acquired Star Filled Studios, a two-person studio, to open a San Francisco office.
Sources: en.wikipedia.org
=== Bibliography === Aerei da combattimento della Seconda Guerra Mondiale (in Italian). Novara, Italy: De Agostini Editore, 2005. Anderson, Peter N. Mustangs of the RAAF and RNZAF. Sydney, Australia: A.H. & A.W. Reed Pty Ltd, 1975. ISBN 0-589-07130-0. Angelucci, Enzo and Peter Bowers. The American Fighter: The Definitive Guide to American Fighter Aircraft from 1917 to the Present. New York: Orion Books, 1985. ISBN 0-517-56588-9. Aro, Chuck and Colin Aro. "World's Fastest Mustangs". Air Enthusiast. No. 13, August–November 1980. pp. 56–62. ISSN 0143-5450 Birch, David. Rolls-Royce and the Mustang. Derby, UK: Rolls-Royce Heritage Trust, 1987. ISBN 0-9511710-0-3. Bowen, Ezra. Knights of the Air (Epic of Flight). New York: Time-Life Books, 1980. ISBN 0-8094-3252-8. Borth, Christy. Masters of Mass Production. Indianapolis, Indiana: Bobbs-Merrill Co., 1945. Bowman, Martin W. P-51 Mustang vs Fw 190: Europe 1943–45. Oxford, UK: Osprey Publishing, 2007. ISBN 1-84603-189-3. Boylan, Bernard. Development of the Long Range Escort Fighter. Washington, D.C.: USAF Historical Division, Research Studies Institute, Air University, 1955. Retrieved: 15 July 2014. Boyne, Walter J. Clash of Wings. New York: Simon & Schuster, 1994. ISBN 0-684-83915-6. Breffort, Dominique with André Jouineau. Le North-American P-51 Mustang – de 1940 à 1980 (Avions et Pilotes 5)(in French). Paris: Histoire et Collections, 2003. ISBN 2-913903-80-0. Bridgman, Leonard, ed. "The North American Mustang." Jane's Fighting Aircraft of World War II. London: Studio, 1946. ISBN 1-85170-493-0.
== Phase 1 == The first phase of the Protein Structure Initiative (PSI-1) lasted from June 2000 until September 2005, and had a budget of $270 million funded primarily by NIGMS with support from the National Institute of Allergy and Infectious Diseases. PSI-1 saw the establishment of nine pilot centers focusing on structural genomics studies of a range of organisms, including Arabidopsis thaliana, Caenorhabditis elegans and Mycobacterium tuberculosis. During this five-year period over 1,100 protein structures were determined, over 700 of which were classified as "unique" due to their < 30% sequence similarity with other known protein structures. The primary goal of PSI-1, to develop methods to streamline the structure determination process, resulted in an array of technical advances. Several methods developed during PSI-1 enhanced expression of recombinant proteins in systems like Escherichia coli, Pichia pastoris and insect cell lines. New streamlined approaches to cell cloning, expression and protein purification were also introduced, in which robotics and software platforms were integrated into the protein production pipeline to minimize required manpower, increase speed, and lower costs.
Tourism is a significant contributor to the Romanian economy, generating around 5% of GDP. The number of tourists has been rising steadily, reaching 9.33 million foreign tourists in 2016, according to the Worldbank. Tourism in Romania attracted €400 million in investments in 2005. More than 60% of the foreign visitors in 2007 were from other EU countries. The popular summer attractions of Mamaia and other Black Sea Resorts attracted 1.3 million tourists in 2009. Among Romania's spa towns and resorts are Buziaș, Băile Călacea, Moneasa, Băile Lipova, Călimănești, Amara, and Geoagiu-Băi. At the same time, seaside resorts such as Eforie, Mangalia, Saturn, Venus, Neptun, Olimp, and Mamaia (sometimes also called the Romanian Riviera) are among the main tourist attractions during the summer. Most popular skiing resorts are along the Valea Prahovei, Muntele Mic, Semenic, Straja and Poiana Brașov. Wine tourism is represented by areas such as Recaș, Silagiu, Odobești, Drăgășani, and Podgoria Aradului. Castles, fortifications, or strongholds as well as preserved medieval Transylvanian cities or towns such as Timișoara, Cluj-Napoca, Sibiu, Brașov, Alba Iulia, Baia Mare, Bistrița, Mediaș, Cisnădie, Sebeș, or Sighișoara also attract a large number of tourists. Bran Castle, near Brașov, is one of the most famous attractions in Romania, drawing hundreds of thousands of tourists every year as it is often (falsely) advertised as being Dracula's Castle. Other attractions include the Danube Delta or the Sculptural Ensemble of Constantin Brâncuși at Târgu Jiu.
Sources: en.wikipedia.org
=== Mechanisms === In vitro transcription (IVT) is performed on a linearized DNA plasmid template containing the targeted coding sequence. Then, naked mRNA or mRNA complexed in a nanoparticle will be delivered systemically or locally. Subsequently, a part of the exogenous naked mRNA or complexed mRNA will go through cell-specific mechanisms. Once in the cytoplasm, the IVT mRNA is translated by the protein synthesis machinery. There are two identified RNA sensors, toll-like receptors (TLRs) and the RIG-I-like receptor family. TLRs are localized in the endosomal compartment of cells, such as DCs and macrophages. RIG-I-like family is as a pattern recognition receptor (PRR). However, the immune response mechanisms and process of mRNA vaccine recognition by cellular sensors and the mechanism of sensor activation are still unclear.
=== Non-specific biotinylation === Photoactivatable biotinylation reagents are ideal when primary amines, sulfhydryls, carboxyls and carbohydrates are not available for labeling. These reagents rely on aryl azides, which become activated by ultraviolet light (UV; >350 nm), which then react at C-H and N-H bonds. Because these types of bonds occur independent of the type of amino acid, this type of biotinylation is termed "non-specific". Photoactivatable biotinylation reagents can also be used to activate biotinylation at specific times in an experiment or during certain reaction conditions, by simply exposing the reaction to UV light at the specific time or condition.
=== 20 December === President Putin stated that the situation was "extremely difficult" in the four areas of Russia-annexed Ukraine. Putin ordered the Federal Security Services to step up surveillance at the country's borders to combat "emergence of new threats" from abroad and traitors. President Zelenskyy visited the Bakhmut region. Russian energy exporter Gazprom said that despite a fatal explosion at the Urengoy–Pomary–Uzhhorod pipeline they were able to supply gas to their customers using parallel pipelines without any shortages.
Chester Fisher died in 1965 at age 84. His sons maintained leadership of the company, with Aiken becoming Chairman and Benjamin becoming president. The youngest son, James Fisher, had the title Senior Vice President. Fisher Scientific Company issued its first public stock in 1965, and that year the company had $58 million in sales and close to a million customer transactions. In 1968 Fisher shares were listed on the New York Stock Exchange. In 1965 the company introduced the Differential Thermalyzer, a differential thermal analysis instrument. It acquired Pfeiffer Glass, Inc. in 1966, a manufacturer of high accuracy volumetric pipettes. The company released the Photometric Titralyzer that year, and a Hem-alyzer in 1968. In 1968, it purchased Massachusetts-based Jarrell-Ash Company, a producer of optical instrumentation, particularly for emission and atomic absorption spectroscopy. It acquired Chicago-based Stansi Scientific Company in 1967, expanding into educational science supplies. In 1976, Fisher Scientific established an Instrument Service Division. Fisher was acquired by Morristown, New Jersey–based Allied Corporation in 1981 for $330 million. At this time Benjamin R. Fisher was Chairman of the company, having gained the position in 1975 upon Aiken's retirement. Operating as a subsidiary of Allied Corporation (and later AlliedSignal Inc., and The Henley Group), Fisher established a Biotechnology Division in 1985. In 1991, The Henley Group sold a majority interest in Fisher through a public stock offering.
Sources: en.wikipedia.org
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.
Reversed-phase HPLC and mass spectrometry are standard checks. They confirm peptide purity and molecular mass, but they do not by themselves demonstrate biological activity.
Synthesis, purification, and handling conditions can differ, leading to variations in purity and salt content. Certificates of analysis help, but independent testing is often needed for verification.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.